Castle Biosciences, Inc. (NASDAQ:CSTL) Stake Boosted by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 2.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,538,520 shares of the company's stock after purchasing an additional 40,377 shares during the quarter. Principal Financial Group Inc. owned about 5.57% of Castle Biosciences worth $43,879,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CSTL. Perkins Capital Management Inc. boosted its holdings in shares of Castle Biosciences by 5.0% in the third quarter. Perkins Capital Management Inc. now owns 32,640 shares of the company's stock valued at $931,000 after acquiring an additional 1,550 shares during the period. Harbor Capital Advisors Inc. raised its position in Castle Biosciences by 11.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 153,907 shares of the company's stock valued at $4,389,000 after purchasing an additional 15,200 shares during the last quarter. US Bancorp DE raised its position in Castle Biosciences by 1,889.2% in the 3rd quarter. US Bancorp DE now owns 4,615 shares of the company's stock valued at $132,000 after purchasing an additional 4,383 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Castle Biosciences by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company's stock valued at $152,000 after purchasing an additional 2,093 shares during the last quarter. Finally, First Bank & Trust purchased a new stake in Castle Biosciences in the 3rd quarter valued at $261,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Castle Biosciences

In other news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $29.44, for a total transaction of $231,604.48. Following the transaction, the director now directly owns 5,700 shares in the company, valued at $167,808. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $29.44, for a total transaction of $231,604.48. Following the completion of the sale, the director now owns 5,700 shares of the company's stock, valued at approximately $167,808. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Derek J. Maetzold sold 986 shares of the stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $30.27, for a total transaction of $29,846.22. Following the completion of the sale, the insider now directly owns 93,636 shares of the company's stock, valued at $2,834,361.72. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,318 shares of company stock worth $478,124 in the last three months. Company insiders own 7.20% of the company's stock.

Castle Biosciences Trading Up 1.5 %

NASDAQ:CSTL traded up $0.49 on Monday, reaching $33.78. The stock had a trading volume of 413,462 shares, compared to its average volume of 325,397. The company has a market cap of $946.18 million, a price-to-earnings ratio of 169.26 and a beta of 0.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.92. The firm's fifty day moving average is $30.92 and its two-hundred day moving average is $25.95. Castle Biosciences, Inc. has a 12-month low of $16.51 and a 12-month high of $35.84.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.14. The business had revenue of $85.78 million for the quarter, compared to analyst estimates of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. During the same period in the prior year, the firm posted ($0.26) EPS. Equities analysts expect that Castle Biosciences, Inc. will post -0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on CSTL shares. Stephens reiterated an "overweight" rating and issued a $37.00 price target on shares of Castle Biosciences in a research report on Tuesday, August 6th. KeyCorp upped their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Scotiabank upped their price target on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a "sector outperform" rating in a research report on Wednesday, November 6th. Robert W. Baird boosted their price objective on shares of Castle Biosciences from $37.00 to $39.00 and gave the company an "outperform" rating in a research note on Tuesday, November 5th. Finally, Canaccord Genuity Group boosted their price objective on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday, October 29th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $37.88.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.